About E3x Bio

About company

E3x Bio is the first company with exclusive focus on the development of inhibitors and activators of E3 Ubiquitin (Ub) ligases for drug discovery and development. This class of medically important enzymes is considered an important target for diseases ranging from cancer to neurodegeneration, but has been inaccessible to high-throughput drug screening because the current assays are cumbersome, indirect, and rely on a complex reaction mixture than can be complicated by multiple protein activities. E3X Bio’s streamlined screening paradigm and direct cellular and animal model assays, allow a simplified and pragmatic drug discovery approach to identify first-in-class small molecules specifically directed towards Ub E3 HECT ligases.